What is the recommended dosage of melatonin (N-acetyl-5-methoxytryptamine) for adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Melatonin Dosing Recommendations for Adults

For adults with insomnia, the recommended melatonin dose is 2 mg, though this is not strongly supported by evidence as the American Academy of Sleep Medicine suggests against using melatonin for primary insomnia in adults. 1

Adult Dosing Guidelines

  • For adults with Delayed Sleep-Wake Phase Disorder (DSWPD), a dose of 5 mg taken between 19:00-21:00 for 28 days is recommended 2
  • For general sleep disorders in adults, starting with 3 mg of immediate-release melatonin with dose titration in 3 mg increments if needed is suggested 2
  • For elderly patients (>55 years), prolonged-release melatonin at 2 mg has shown some benefit, though the evidence is considered low quality 2, 3
  • Doses between 1-6 mg appear effective for improving sleep in older adults, with no clear dose-response relationship identified 4

Pediatric Dosing Guidelines

  • For children with DSWPD without comorbidities, use weight-based dosing of 0.15 mg/kg taken 1.5-2.0 hours before habitual bedtime 1, 2
  • For children with DSWPD and psychiatric comorbidities, use fast-release melatonin at 3-5 mg (3 mg if <40 kg; 5 mg if >40 kg) 1, 2

Formulation Considerations

  • Immediate-release formulations appear more effective than slow-release formulations for sleep onset 2, 5
  • Slow-release melatonin (2 mg) was found to be relatively ineffective in clinical trials 6
  • Higher doses (5 mg) may help people fall asleep faster and sleep better compared to lower doses (0.5 mg) 6

Treatment Duration

  • For adults with DSWPD, a treatment duration of 28 days has shown efficacy 2
  • For children without comorbidities, as little as 6 nights of treatment has demonstrated effectiveness 1, 2
  • For children with psychiatric comorbidities, a 4-week treatment duration is recommended 1, 2

Pharmacokinetic Considerations

  • Lower doses of melatonin may be more effective than higher doses due to potential receptor desensitization with higher doses 7
  • The time to maximum concentration (1.3-1.5 hours) and elimination half-life (1.8-2.1 hours) do not differ significantly between low (0.4 mg) and high (4.0 mg) doses 5
  • High doses (4 mg) can maintain elevated melatonin levels for approximately 10 hours, which may extend beyond the typical sleep period 5

Safety and Adverse Effects

  • No serious adverse reactions have been documented in relation to melatonin use across age groups 1, 2
  • Morning grogginess and "hangover" effects are more commonly reported with higher doses 2
  • Caution is advised when prescribing to patients taking warfarin and to patients with epilepsy due to potential interactions 2
  • Choose reputable formulations (such as USP Verified) when possible for more reliable dosing 2, 8

Clinical Algorithm for Melatonin Use

  • For adults with primary insomnia: Not recommended as first-line therapy 1
  • For adults with DSWPD: Start with 3-5 mg taken between 19:00-21:00 for at least 28 days 2
  • For elderly patients with insomnia: Consider 2 mg prolonged-release formulation 2, 3
  • For jet lag prevention: 0.5-5 mg taken at target bedtime at destination (10 pm to midnight) 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Melatonin Treatment for Sleep Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Melatonin in elderly patients with insomnia. A systematic review.

Zeitschrift fur Gerontologie und Geriatrie, 2001

Research

Melatonin for the prevention and treatment of jet lag.

The Cochrane database of systematic reviews, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.